Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Study Summary

This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.

Conditions

Atherosclerotic Cardiovascular Disease

Interventions / Drugs

Atorvastatin Simvastatin Rozuvastatin Ezetimibe Niacin Ciprofibrate Fenofibrate Bezafibrate Evolocumab Alirocumab Inclisiran

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment2382 participants

Primary Completion—

Lead SponsorNovartis Pharmaceuticals

Data Retrieved2026-04-11 02:55:49.151458+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.